Phase II Study of Pembrolizumab in Combination with Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma

Study Overview

This study is for women with advanced or recurrent endometrial cancer using Pembrolizumab in combination with Carboplatin and Paclitaxel chemotherapy.

Study Description

This phase II trial will study the effects of pembrolizumab in combination with carboplatin/paclitaxel for the treatment of subjects with advanced or recurrent endometrial cancer.

Additional Information

Participants will not be paid for their participation.

  • IRB Number: 1711046947 (BTCRC-GYN15-013)
  • Research Study Identifier: TX8472
  • Principal Investigator: Jeanne Schilder, MD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: or call us at (317) 278-2176